Small-interfering RNA targeting proprotein convertase subtilisin/kexin type 9 might promote fatty liver disease and hepatocellular carcinoma through upregulation of CD36

CD36 (SR-B2) as master regulator of cellular fatty acid homeostasis

(2022) Jan F.C. Glatz et al.   CURRENT OPINION IN LIPIDOLOGY

Upregulation of CD36, a Fatty Acid Translocase, Promotes Colorectal Cancer Metastasis by Increasing MMP28 and Decreasing E-Cadherin Expression

(2022) James Drury et al.   Cancers

Gene Therapy Targeting PCSK9

(2022) Julius L. Katzmann et al.   Metabolites

CD36: an emerging therapeutic target for cancer and its molecular mechanisms

(2022) Chengwei Ruan et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Efficacy and Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors as Adjuvant Treatments for Patients with Hypercholesterolemia Treated with Statin: A Systematic Review and Network Meta-analysis

(2022) Yi-Ting Huang et al.   Frontiers in Pharmacology

The Emerging Roles of Intracellular PCSK9 and Their Implications in Endoplasmic Reticulum Stress and Metabolic Diseases

(2022) Paul F. Lebeau et al.   Metabolites

Insight into the Evolving Role of PCSK9

(2022) Mateusz Maligłówka et al.   Metabolites

Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond

(2022) Nabil G. Seidah et al.   Current Atherosclerosis Reports

Inclisiran: How Widely and When Should We Use It?

(2022) Angela Pirillo et al.   Current Atherosclerosis Reports

Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis

(2022) Fausto Petrelli et al.   NEOPLASIA

Network Meta‐Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid‐Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low‐Density Lipoprotein Cholesterol

(2022) Peter P. Toth et al.   Journal of the American Heart Association

PCSK9 Inhibition: From Current Advances to Evolving Future

(2022) Chunping Liu et al.   Cells

CD36-Fatty Acid-Mediated Metastasis via the Bidirectional Interactions of Cancer Cells and Macrophages

(2022) Noorzaileen Eileena Zaidi et al.   Cells

Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis

(2021) R. Scott Wright et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The fatty acid receptor CD36 promotes HCC progression through activating Src/PI3K/AKT axis-dependent aerobic glycolysis

(2021) Xiaoqing Luo et al.   Cell Death & Disease

Transcription factor SOX2 contributes to nonalcoholic fatty liver disease development by regulating the expression of the fatty acid transporter CD36

(2021) Chen Shen et al.   FEBS LETTERS

Clozapine Worsens Glucose Intolerance, Nonalcoholic Fatty Liver Disease, Kidney Damage, and Retinal Injury and Increases Renal Reactive Oxygen Species Production and Chromium Loss in Obese Mice

(2021) Geng-Ruei Chang et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Inclisiran—Silencing the Cholesterol, Speaking up the Prognosis

(2021) Sylwester Rogula et al.   Journal of Clinical Medicine

The Multifaceted Biology of PCSK9

(2021) Nabil G Seidah et al.   ENDOCRINE REVIEWS

Atypical antipsychotic drugs deregulate the cholesterol metabolism of macrophage-foam cells by activating NOX-ROS-PPARγ-CD36 signaling pathway

(2021) Chia-Hui Chen et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma

(2021) Danyu Du et al.   Acta Pharmaceutica Sinica B

Haematologic malignancies associated with clozapine v. all other antipsychotic agents: a pharmacovigilance study in VigiBase®

(2020) Basile Chrétien et al.   PSYCHOLOGICAL MEDICINE

Reprogramming of lipid metabolism in cancer-associated fibroblasts potentiates migration of colorectal cancer cells

(2020) Jin Gong et al.   Cell Death & Disease

Time for a détente in the war on the mechanism of cellular fatty acid uptake

(2020) Jan F. C. Glatz et al.   JOURNAL OF LIPID RESEARCH

PCSK9 rs11591147 R46L Loss‐of‐Function Variant Protects Against Liver Damage in Individuals with NAFLD

(2020) Stefania Grimaudo et al.   LIVER INTERNATIONAL

Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?

(2020) Patricia Rada et al.   Cell Death & Disease

Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)

(2020) David Sinning et al.   Current Cardiology Reports

CD36 upregulates DEK transcription and promotes cell migration and invasion via GSK-3β/β-catenin-mediated epithelial-to-mesenchymal transition in gastric cancer

(2020) Jin Wang et al.   Aging-US

Genetic Inhibition of PCSK9 and Liver Function

(2020) Antoine Rimbert et al.   JAMA Cardiology

CD36 mediates palmitate acid-induced metastasis of gastric cancer via AKT/GSK-3β/β-catenin pathway

(2019) Jiaomeng Pan et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

ER-residential Nogo-B accelerates NAFLD-associated HCC mediated by metabolic reprogramming of oxLDL lipophagy

(2019) Yuan Tian et al.   Nature Communications

Single-cell gene expression analyses reveal distinct self-renewing and proliferating subsets in the leukemia stem cell compartment in acute myeloid leukemia

(2019) Karen Sachs et al.   CANCER RESEARCH

Breast-Associated Adipocytes Secretome Induce Fatty Acid Uptake and Invasiveness in Breast Cancer Cells via CD36 Independently of Body Mass Index, Menopausal Status and Mammary Density

(2019) Maurice Zaoui et al.   Cancers

Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma

(2018) Omar Massoud et al.   Clinics in Liver Disease

Long-chain fatty acid activates hepatocytes through CD36 mediated oxidative stress

(2018) Jun Liu et al.   Lipids in Health and Disease

Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases

(2018) Jonathan G. Stine et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways

(2018) Qing Li et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis

(2017) Chengfeng Qiu et al.   Lipids in Health and Disease

PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans

(2017) Andrea Baragetti et al.   European Journal of Preventive Cardiology

PCSK9 Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and StrokeCLINICAL PERSPECTIVE

(2017) Shia T. Kent et al.   Circulation-Cardiovascular Genetics

PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis

(2016) Anne Langsted et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse LiverSignificance

(2015) Annie Demers et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Elevated free fatty acid uptake via CD36 promotes epithelial-mesenchymal transition in hepatocellular carcinoma

(2015) Aritro Nath et al.   Scientific Reports

Metabolic syndrome in patients taking clozapine: prevalence and influence of catechol-O-methyltransferase genotype

(2014) Yi Zhang et al.   PSYCHOPHARMACOLOGY